Calliditas Therapeutics AB (FRA:LC8) ROCE % : 9.36% (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Calliditas Therapeutics AB ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Calliditas Therapeutics AB's annualized ROCE % for the quarter that ended in Dec. 2023 was 9.36%.

Calliditas Therapeutics AB ROCE % Historical Data

The historical data trend for Calliditas Therapeutics AB's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Calliditas Therapeutics AB ROCE % Chart

Calliditas Therapeutics AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-4.52

-40.97

-37.56

-24.73

-24.70

Calliditas Therapeutics AB Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															-11.14	21.11	-19.11	-47.18	9.36

Calliditas Therapeutics AB ROCE % Calculation

Calliditas Therapeutics AB's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-34.312	/	( ( (177.646 - 29.584)	+	(166.211 - 36.398) )	/ 2 )
	=	-34.312	/	( (148.062	+	129.813)	/ 2 )
	=	-34.312	/	138.9375
	=	-24.70 %

Calliditas Therapeutics AB's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	11.084	/	( ( (136.253 - 29.138)	+	(166.211 - 36.398) )	/ 2 )
	=	11.084	/	( ( 107.115	+	129.813 )	/ 2 )
	=	11.084	/	118.464
	=	9.36 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Calliditas Therapeutics AB (FRA:LC8) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Calliditas Therapeutics AB ROCE % Related Terms

Thank you for viewing the detailed overview of Calliditas Therapeutics AB's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Calliditas Therapeutics AB (FRA:LC8) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Calliditas Therapeutics AB (FRA:LC8) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

CALT:USA CALTX:Sweden CALTXs:UK

Address

Kungsbron 1, D5, Stockholm, SWE, SE-111 22

Website

https://www.calliditas.se

Calliditas Therapeutics AB is a commercial-stage biopharma company focused on identifying, developing, and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with unmet medical needs. The company's pipeline candidate is TARPEYO medication to reduce proteinuria in IgA nephropathy.

Calliditas Therapeutics AB (FRA:LC8) Headlines

No Headlines